Загрузка...
Improving clinical trial design for Duchenne muscular dystrophy
BACKGROUND: Currently, the most promising therapies for Duchenne muscular dystrophy (DMD) are exon skipping and stop codon read-through, two strategies aimed at restoring the expression of dystrophin. A phase 3 clinical trial with drisapersen, a drug designed to induce exon 51-skipping, has failed t...
Сохранить в:
| Опубликовано в: : | BMC Neurol |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4549867/ https://ncbi.nlm.nih.gov/pubmed/26306629 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-015-0408-z |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|